Physician profile
Sarah Morad
NPI 1639876949
$2,315.36
in general payments reported to CMS, 2019-2025
22 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $264 · 2024: $562 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,215 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,215.37 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $669.36 | 2023-2025 | |
| Janssen Biotech, INC. | $353.76 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $218.94 | 2023-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $122.64 | 2024-2025 | Omvoh, Zepbound |
| Ardelyx, INC. | $121.92 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $117.10 | 2024-2025 | |
| Madrigal Pharmaceuticals | $110.16 | 2025 | Rezdiffra |
| Pfizer INC. | $91.19 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $71.51 | 2025 | Zenpep, Vowst |
| Qol Medical, LLC | $65.68 | 2025 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $56.68 | 2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.89 | 2024-2025 | Xifaxan, Plenvu |
| Intercept Pharmaceuticals, INC. | $50.00 | 2025 | |
| Ferring Pharmaceuticals INC. | $30.68 | 2023 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $30.27 | 2023 | Dupixent |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $29.19 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $28.62 | 2023 | Dificid |
| Evoke Pharma, INC. | $26.18 | 2023-2024 | Gimoti |
| Amgen INC. | $20.85 | 2023 | Avsola, Amjevita |
| Vivus LLC | $16.84 | 2025 | Pancreaze |
| Nestle Healthcare Nutrition INC. | $16.73 | 2023 | |
| Celltrion USA INC. | $14.17 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Morad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.